|
|
|
市場調查報告書
慢性封閉性肺疾病（COPD）的全球市場
Chronic Obstructive Pulmonary Disease
|
慢性封閉性肺疾病（COPD）的全球市場 是由出版商Global Industry Analysts, Inc.在2010年02月所出版的。
這份英文市場調查報告書包含Pages: 432 價格從美金3450起跳。
本報告書內容包括:COPD市場的分析、同病患的經濟負擔及治療方法、治療藥物開發趨勢、全球各地區的趨勢、主要企業的介紹和競爭趨勢、內容綱要摘記如下:
第1章 介紹・調查方法・產品定義
第2章 實施摘要
- 業界概要
- 市場趨勢
- 現在及未來分析
- 市場概要
- 市場展望
- 維持療法
- 炎症治療：尚未被滿足的需求
- 競爭環境
- COPD的藥物生產線
- COPD：病況和治療
- 概要
- 風險因素
- 病況和症狀
- 診斷
- 錯誤認知
- 治療指南
- 治療法
- 近年的業界活動
- 產品認可／引進
- 主要企業
- AstraZeneca Plc
- Boehringer Ingelheim GmbH
- GlaxoSmithKline PLC
- Novartis AG
- Nycomed S.C.A. SICAR
- Schering-Plough Corporation
- Sepracor, Inc.
- Vectura Group plc
- 全球的市場展望
第3章 市場
第4章 競爭環境
Abstract
This report analyzes the worldwide markets for Chronic Obstructive Pulmonary
Disease in US$ Million. The report provides separate comprehensive analytics
for US and Rest of World. Annual forecasts are provided for each region for
the period 2006 through 2015. The report profiles 53 companies including many
key and niche players worldwide such as AstraZeneca Plc, Boehringer Ingelheim
GmbH, GlaxoSmithKline PLC, Novartis AG, Nycomed S.C.A. SICAR, Schering-Plough
Corporation, Sepracor, Inc., and Vectura Group plc. Market data and analytics
are derived from primary and secondary research. Company profiles are mostly
extracted from URL research and reported select online sources.
Table of Contents
I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS
- Study Reliability and Reporting Limitations
- Disclaimers
- Data Interpretation & Reporting Level
- Quantitative Techniques & Analytics
- Product Definitions and Scope of Study
II. EXECUTIVE SUMMARY
1. INDUSTRY OVERVIEW
- Respiratory Diseases - Common and Serious
- COPD - A Debilitating Disease
- COPD Fact File: Prevalence
- COPD Fact File: Mortality
- COPD Fact File: Smoking as the Leading Cause
- COPD - Economic Burden
- Table 1: COPD Related Costs (Including Direct and Indirect Costs) Per
Patient Aged Over 40 Years (includes corresponding Graph/Chart)
2. MARKET DYNAMICS
- Current & Future Analysis
- Market Overview
- Market Outlook
- Maintenance Therapies to Continue Lead
- Treatment of Inflammation - An Unmet Need
- Competitive Landscape
- Table 2: World COPD Market by Major Drugs (2006): Value Sales for Advair,
Spiriva, Combivent, Symbicort, and Atrovent (includes corresponding
Graph/Chart)
- Table 3: World Leading Inhaled COPD/Asthma Drugs (2007): Value Sales for
Advair, Symbicort, Pulmicort, Flovent, Asmanex, Serevent, Foradil, Spiriva,
Atrovent, Combivent (includes corresponding Graph/Chart)
3. COPD PIPELINE
- The COPD Drug Discovery
- Bronchodilators Pipeline
- List of Potential Bronchodilator (LABA Inhaled) Candidates in Drug
Development Pipeline
- List of Potential Bronchodilator (LAMA Inhaled) Candidates in Drug
Development Pipeline
- Anti-inflammatories Pipeline
- List of Potential Anti-inflammatory (Inhaled Corticosteroid) Candidates in
Drug Development Pipeline
- List of Potential Anti-inflammation Agents (Anti- Leukotriene-oral)
Candidates in Drug Development Pipeline
- List of Potential Anti-inflammation Agents (Phophodiesterase-4
Inhibitors-oral) Candidates in Drug Development Pipeline
- Combination Products Pipeline
- List of Potential Combination Products (LABA/ICS Combination-inhaled) in
Drug Development Pipeline
- List of Potential Combination Products (LABA/LAMA) in Drug Development
Pipeline
- Pipeline Drugs with Novel Mode of Action
- List of Novel Approaches to COPD Treatment in Drug Development Pipeline
4. CHRONIC OBSTRUCTIVE PULMONARY DISEASE - THE CONDITION AND TREATMENT
- Chronic Obstructive Pulmonary Disease - Synopsis
- The Normal Lung Functioning
- The Lung Functioning in COPD
- Risk Factors
- Signs and Symptoms
- Diagnosis
- The Misconception
- Management Guidelines
- GOLD Recommended Management of COPD: Stage 0
- GOLD Recommended Management of COPD: Stage II
- GOLD Recommended Management of COPD: Stage III
- GOLD Recommended Management of COPD: Stage IV
- Treatment Options
- Therapeutic Options
- Bronchodilators
- Beta2-agonists
- Short-acting Beta2-agonists
- List of Prescription Short-acting Beta2-agonists
- Long-acting Beta2-agonists
- A Comparison of Leading Two LABAs : Salmeterol and Formoterol
- List of Prescription Long-acting Beta2-agonists
- Anticholinergics
- Short-acting Anticholinergics
- List of Short-acting Prescription Anticholinergics
- Long-acting Anticholinergics
- Methylxanthines
- List of Methylxanthines and Their Route of Administration
- Anti-inflammatories
- Inhaled Steroids
- List of Inhaled Steroids and their Route of Administration
- Oral Steroids
- List of Tablet Steroids and their Route of Administration
- Combination Therapies
- List of Prescription Combination Products
5. RECENT INDUSTRY ACTIVITY
- AEterna Zentaris Signs Agreement to Acquire All AEZS-130 Assets from Ardana
- Nycomed and Forest Sign Exclusive US Accord for Daxas
- Schering-Plough Revises Collaboration with Novartis
- AstraZeneca Extends Research Collaboration with Dynavax
- GlaxoSmithKline and Mitsubishi Tanabe Sign Co-marketing Deal for Adoair
- SeQual Technologies and AOTI Form Partnership
- Revotar Biopharma Secures Research Grant
- Argenta Discovery Announces Milestone Achievement
- Vectura Receives Milestone Payment
- Vectura Inaugurates New Laboratory Facility
- MicroDose Technologies Announces Name Change to MicroDose Therapeutx
- Boehringer Ingelheim to Take Over Actimis Pharmaceuticals
- Novartis to Acquire Pulmonary Unit of Nektar
- Tongjitang Chinese Medicine Plans Pulante Pharma Acquisition
- Sepracor, Arrow Announce Global Agreement for Combination Inhalation
Solution
- Nycomed Canada and Chiesi Farmaceutici form Licensing Agreement
- Sepracor, Arrow Sign Technology License and Development Agreement
- Teva Specialty Pharmaceuticals Announces Respiratory Deal with UCB
- 3M Drug Delivery and Cambridge Consultants Sign Exclusive Agreement
- Sanofi-aventis Announces Collaboration with Johns Hopkins University
- Lupin Enters Long-Term Accord with Forest Laboratories
- Ingen Signs Agreements with Batterjee Medical and Progressive International
- AstraZeneca, Silence Therapeutics Enter into Collaboration
- Vectura Announces Sandoz as Partner for VR315 and VR632
- Air Products Divests A&J Care and COPD Services
- Parion Sciences Receives Milestone Payment for Pulmonary Disease Drug
- Almirall Receives Payment from Forest Laboratories for Aclidinium Bromide
- AstraZeneca Announces EPO Ruling for Symbicort Patent
- Inverness Medical Announces Alere Medical Acquisition
- Respironics Takes Over J.H. Emerson
- Alkermes Enters into Joint Collaboration with Indevus Pharmaceuticals
- Aradigm Enters into Collaboration Agreement with CyDex
- Critical Therapeutics and Dey Sign Co-Promotion Agreement
6. PRODUCT APPROVALS / INTRODUCTIONS
- AstraZeneca Wins US Approval for Symbicort
- Novartis Secures EC Approval for New Oral COPD Drug, Onbrez Breezhaler
- Nycomed Submits MMA for New Oral Drug, Daxas, to the EMEA
- Nycomed Files for Daxas(r) Approval with the FDA
- Novartis Receives FDA' s CRL for Investigational COPD Bronchodilator, QAB149
- 3M Drug Delivery Launches Two New Dry Powder Inhalers
- GlaxoSmithKline Announces FDA Approval of Advair Diskus 250/50
- Dey' s Perforomist Inhalation Solution Wins FDA Approval for COPD
- Boehringer, Pfizer Win EU Approval for Spiriva Respimat
7. FOCUS ON SELECT PLAYERS
- AstraZeneca Plc (UK)
- Boehringer Ingelheim GmbH (Germany)
- GlaxoSmithKline PLC (UK)
- Novartis AG (Switzerland)
- Nycomed S.C.A. SICAR (Switzerland)
- Schering-Plough Corporation (US)
- Sepracor, Inc. (US)
- Vectura Group plc (UK)
8. GLOBAL MARKET PERSPECTIVE
- Table 4: World Recent Past, Current & Future Analysis for Chronic
Obstructive Pulmonary Disease by Geographic Region - US and Rest of World
Markets Independently Analyzed with Annual Revenue Figures in US$ Million for
Years 2006 through 2015 (includes corresponding Graph/Chart)
- Table 5: World 10-Year Perspective for Chronic Obstructive Pulmonary
Disease by Geographic Region - Percentage Breakdown of Dollar Revenues for the
US and Rest of World Markets for 2006, 2009 & 2015
III. MARKET
1. THE UNITED STATES
- A. Market Analysis
- Current & Future Analysis
- COPD - Prevalence
- Table 6: COPD Prevalence Data in American Adults Aged 18 Years and Over
in the US (includes corresponding Graph/Chart)
- Chronic Bronchitis Data
- Table 7: Chronic Bronchitis - Breakdown of Chronic Bronchitis Patients
by Gender: 2007
- Table 8: Chronic Bronchitis - Breakdown of Chronic Bronchitis Patients
by Age Group: 2007 (includes corresponding Graph/Chart)
- Table 9: Chronic Bronchitis - Breakdown of Chronic Bronchitis Patients
by Ethnicity: 2007 (includes corresponding Graph/Chart)
- Emphysema Data
- Table 10: Emphysema - Breakdown of Chronic Bronchitis Patients by
Gender: 2007
- Table 11: Emphysema - Breakdown of Chronic Bronchitis Patients by Age
Group: 2007 (includes corresponding Graph/Chart)
- Table 12: Emphysema - Breakdown of Chronic Bronchitis Patients by
Ethnicity: 2007 (includes corresponding Graph/Chart)
- Market Overview
- Table 13: US COPD Market by Major Drugs (2006): Value Sales for Advair,
Spiriva, Combivent, Flovent, Atrovent, and Serevent (includes corresponding
Graph/Chart)
- Table 14: US COPD Market by Major Drugs (2006): Total Prescriptions for
Advair, Spiriva, Combivent, Flovent, Atrovent, and Serevent (includes
corresponding Graph/Chart)
- Table 15: US COPD/Asthma Market by Drug Class (2007 and 2008): Value
Sales for Inhaled Steroids/ Combinations, Inhaled Beta Agonists,
Leukotrines, and Inhaled Anticholinergics/NSAIDs (includes corresponding
Graph/Chart)
- Table 16: US COPD/Asthma Market by Drug Class (2007 and 2008): Total
Prescriptions for Inhaled Steroids/ Combinations, Inhaled Beta Agonists,
Leukotrines, and Inhaled Anticholinergics/NSAIDs (includes corresponding
Graph/Chart)
- Table 17: US COPD/Asthma Market by Leading Drugs (2007 and 2008): Value
Sales for Advair/Diskus, Singulair, Spiriva, Symbicort, Pulmicort, and
Flovent (includes corresponding Graph/Chart)
- Table 18: US COPD/Asthma Market by Leading Drugs (2007 and 2008): Total
Number of Prescriptions for Advair/Diskus, Singulair, Spiriva, Symbicort,
Pulmicort, and Flovent (includes corresponding Graph/Chart)
- Patient Non-compliance Hinders Market Growth
- Lack of Awareness - A Major Bottleneck for Market Growth
- HFA-propelled Inhalers End the CFC-propelled Inhalers Era
- Strategic Corporate Developments
- Product Approvals / Launches
- Select Players
- B. Market Analytics
- Table 19: US Recent Past, Current & Future Analysis for Chronic
Obstructive Pulmonary Disease - Annual Revenue Figures in US$ Million for
Years 2006 through 2015 (includes corresponding Graph/Chart)
2. REST OF WORLD
- A. Market Analysis
- Current & Future Analysis
- China
- Market Overview
- Strategic Corporate Developments
- Product Approvals
- Select Players
- B. Market Analytics
- Table 20: Rest of World Recent Past, Current & Future Analysis for
Chronic Obstructive Pulmonary Disease - Annual Revenue Figures in US$
Million for Years 2006 through 2015 (includes corresponding Graph/Chart)
IV. COMPETITIVE LANDSCAPE
|
 |
